A screening program for cervical cancer in a rural Indian district uses HPV DNA testing (high-sensitivity test) on 10,000 women. The test has a sensitivity of 98% and specificity of 85%. Among the 2,500 women who test positive, only 200 actually have cervical intraepithelial neoplasia (CIN) grade 2 or higher on colposcopy. The district health officer wants to reduce unnecessary colposcopy referrals. What is the most appropriate next step?

Explanation

## Problem Analysis **Key Point:** The HPV test has high sensitivity (98%) but moderate specificity (85%), resulting in a high false-positive rate (2,300 false positives out of 2,500 positive tests). The positive predictive value (PPV) is only 8% (200/2,500), meaning 92% of positive tests are false positives. ## Calculate Positive Predictive Value $$PPV = \frac{TP}{TP + FP} = \frac{200}{200 + 2300} = \frac{200}{2500} = 8\%$$ This low PPV explains why most HPV-positive women do not have disease and are undergoing unnecessary colposcopy. ## Why Reflex Cytology (Two-Stage Strategy) is Optimal **High-Yield:** A two-stage screening strategy improves specificity and PPV without sacrificing sensitivity: - **Stage 1:** HPV DNA testing (high sensitivity, moderate specificity) - **Stage 2:** Reflex cytology in HPV-positive women (adds specificity; colposcopy only if cytology is abnormal) ### Comparison of Strategies | Strategy | Sensitivity | Specificity | PPV | False Positives | Colposcopy Referrals | |----------|-------------|-------------|-----|-----------------|---------------------| | HPV alone | 98% | 85% | 8% | 2,300 | 2,500 | | HPV + reflex cytology | ~98% | ~95% | ~30–40% | ~600–900 | ~600–900 | | Repeat HPV | 98% | 85% | 8% | 2,300 | 2,500 | | Lower cutoff | 90% | 90% | ~15% | 1,500 | 1,500 | **Clinical Pearl:** Reflex cytology is the gold-standard approach in cervical cancer screening programs worldwide (including India's NACO guidelines). It reduces unnecessary colposcopy by ~60–70% while maintaining high sensitivity for detecting CIN 2+. ## Why This Works 1. **Sequential testing:** HPV detects infection; cytology detects cellular abnormality (higher specificity for disease). 2. **Cost-effective:** Cytology is cheaper than colposcopy and reduces burden on colposcopy services. 3. **Guideline-aligned:** Recommended by WHO, ASCCP, and Indian cervical cancer screening guidelines. ```mermaid flowchart TD A[10,000 women]:::outcome --> B[HPV DNA testing]:::action B --> C{HPV positive?}:::decision C -->|No 7,500| D[Routine screening in 3 years]:::action C -->|Yes 2,500| E[Reflex Pap smear/cytology]:::action E --> F{Cytology abnormal?}:::decision F -->|No 1,700| G[HPV retest in 1 year]:::action F -->|Yes 800| H[Colposcopy]:::action H --> I{CIN 2+ present?}:::decision I -->|Yes 200| J[Treatment]:::action I -->|No 600| K[Surveillance]:::action ``` **Warning:** ~~Repeating HPV testing~~ does not improve specificity; it only confirms the same result. ~~Lowering the cutoff threshold~~ worsens specificity further. ~~Using a more expensive confirmatory assay~~ is not cost-effective for a public health program.